These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation. Lusher J, Abildgaard C, Arkin S, Mannucci PM, Zimmermann R, Schwartz L, Hurst D. J Thromb Haemost; 2004 Apr; 2(4):574-83. PubMed ID: 15102011 [Abstract] [Full Text] [Related]
12. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E. J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823 [Abstract] [Full Text] [Related]
14. The uptake of recombinant Factor VIII in the Netherlands. Zwart-van Rijkom JE, Plug I, Rosendaal FR, Leufkens HG, Broekmans AW, Study Group Haemophilia in The Netherlands. Br J Haematol; 2002 Nov; 119(2):332-41. PubMed ID: 12406065 [Abstract] [Full Text] [Related]
15. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A. Musso R. Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127 [Abstract] [Full Text] [Related]
16. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII. Toschi V. Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394 [Abstract] [Full Text] [Related]
19. Characterization of recombinant factor VIII and a recombinant factor VIII deletion mutant using a rabbit immunogenicity model system. Esmon PC, Kuo HS, Fournel MA. Blood; 1990 Oct 15; 76(8):1593-600. PubMed ID: 1698481 [Abstract] [Full Text] [Related]